Go Pro

Versigent (NYSE:VGNT) Given Average Rating of "Moderate Buy" by Brokerages

Versigent logo with background
Image from MarketBeat Media, LLC.

Key Points

  • Analysts rate Versigent “Moderate Buy”: Of 14 covering firms, 11 recommend buying and three advise holding. The average 12-month price target is $54, above the stock’s $46.56 opening price.
  • Versigent exceeded quarterly expectations, reporting $1.92 earnings per share versus the $1.58 consensus estimate and revenue of $2.44 billion against expectations of $2.29 billion.
  • The company declared a quarterly dividend of $0.13 per share, equivalent to $0.52 annually and a 1.1% yield, while several institutional investors opened new positions during the second quarter.
  • Five stocks we like better than Versigent.

Shares of Versigent (NYSE:VGNT - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the fourteen ratings firms that are currently covering the company, MarketBeat reports. Three investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $54.00.

A number of analysts have recently commented on the company. TD Cowen boosted their price objective on Versigent from $49.00 to $58.00 and gave the company a "buy" rating in a research report on Wednesday, August 5th. UBS Group decreased their target price on Versigent from $58.00 to $55.00 and set a "buy" rating on the stock in a research report on Thursday, July 9th. Argus lifted their price target on shares of Versigent from $50.00 to $54.00 and gave the company a "buy" rating in a research note on Thursday, August 13th. Weiss Ratings assumed coverage on shares of Versigent in a report on Wednesday, August 5th. They issued a "hold (c)" rating for the company. Finally, The Goldman Sachs Group restated a "buy" rating and set a $59.00 price objective on shares of Versigent in a research report on Wednesday, August 5th.

Check Out Our Latest Research Report on Versigent

Versigent Stock Down 1.8%

NYSE:VGNT opened at $46.56 on Friday. The company has a debt-to-equity ratio of 7.29, a current ratio of 1.40 and a quick ratio of 1.09. Versigent has a 52 week low of $26.34 and a 52 week high of $50.88. The company's 50-day simple moving average is $43.02. The firm has a market cap of $3.30 billion and a PE ratio of 24.25.

Versigent (NYSE:VGNT - Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The company reported $1.92 earnings per share for the quarter, topping analysts' consensus estimates of $1.58 by $0.34. The business had revenue of $2.44 billion during the quarter, compared to analyst estimates of $2.29 billion. Sell-side analysts expect that Versigent will post 7.23 earnings per share for the current fiscal year.

Versigent Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, September 18th. Stockholders of record on Friday, September 4th will be given a $0.13 dividend. The ex-dividend date is Friday, September 4th. This represents a $0.52 annualized dividend and a dividend yield of 1.1%.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of VGNT. Nan Shan Life Insurance Co. Ltd. acquired a new stake in Versigent in the 2nd quarter worth about $5,400,000. Wellington Management Group LLP purchased a new stake in Versigent during the 2nd quarter worth approximately $940,000. Ancora Advisors LLC purchased a new stake in Versigent during the 2nd quarter worth approximately $4,197,000. Finally, Kintegral Advisory LLC acquired a new position in shares of Versigent during the second quarter valued at approximately $224,000.

About Versigent

(Get Free Report)

Versigent PLC is involved in the design, manufacturing and delivery of low and high voltage power electrical architectures. Versigent PLC is based in SCHAFFHAUSEN, Switzerland.

Further Reading

Analyst Recommendations for Versigent (NYSE:VGNT)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Should You Invest $1,000 in Versigent Right Now?

Before you consider Versigent, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Versigent wasn't on the list.

While Versigent currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Will Be Magnificent in 2026 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines